The Dilated Cardiomyopathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Dilated Cardiomyopathy: An Overview
Dilated Cardiomyopathy (DCM) is the most common type of non-ischemic heart muscle disease, occurring mostly in adults. It affects the lower chamber of the ventricle and the upper chamber of the atria of the heart.
The WHO defines DCM as a serious cardiac disorder in which structural or functional abnormalities of the heart muscle can lead to substantial morbidity and mortality owing to complications such as heart failure and arrhythmia.
Currently, there is no approved therapy for the treatment of DCM, however, off-label therapies like beta-blockers, angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors (ACEi), aldosterone antagonists, and diuretics are available to help control symptoms and prevent complications.
Dilated Cardiomyopathy Market Key Facts
-
According to the research study of Hershberger, Hedges, & Morales (2013), DCM is more common than HCM and is found in more than 1 of 2,500 individuals.
-
According to DelveInsight estimate, the total prevalent population of Dilated Cardiomyopathy in the 7MM was 2,523,800+ in 2020.
-
Among the 7MM, the highest number of prevalent cases of Dilated cardiomyopathy were recorded in the United States.
-
Among the European 5 countries, the Germany had highest diagnosed cases of Dilated cardiomyopathy with 81,200+ cases in 2020, followed by France, Italy, and the United Kingdom. On the other hand, Spain had the lowest diagnosed cases of Dilated cardiomyopathy in 2020.
Dilated Cardiomyopathy (DCM) market is expected to increase during the forecast period owing to the increasing prevalence rate of heart disease, increasing healthcare spending, and emerging treatment options.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Dilated Cardiomyopathy market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Dilated Cardiomyopathy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Dilated Cardiomyopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Dilated Cardiomyopathy (DCM) Epidemiology Segmentation –
-
Total Prevalent Population
-
Total Diagnosed Population
-
Familial and non-familial cases of Dilated Cardiomyopathy
-
Total Treated Cases of Dilated Cardiomyopathy
Dilated Cardiomyopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dilated Cardiomyopathy market or expected to get launched during the study period. The analysis covers Dilated Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dilated Cardiomyopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm-market-insights
Dilated Cardiomyopathy Therapeutics Analysis
The Dilated Cardiomyopathy (DCM) market dynamic is anticipated to change in the coming years owing to the rise in healthcare spending across the world. At present some of the key players worldwide are involved in developing drugs for Dilated Cardiomyopathy (DCM).
Some of the key companies in the Dilated Cardiomyopathy (DCM) Market include:
-
Vericel
-
Pfizer
-
MyoKardia Inc.
-
Berlin Cures
-
Capricor Therapeutics
-
Cumberland Pharmaceuticals
And many others
Dilated Cardiomyopathy (DCM) Therapies covered in the report include:
-
BC 007
-
Ifetroban
-
CAP-1002
-
Ixmyelocel-T
-
PF-07265803/ARRY-371797
-
MYK-491
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies –
https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm-market-insights
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dilated Cardiomyopathy Competitive Intelligence Analysis
4. Dilated Cardiomyopathy Market Overview at a Glance
5. Dilated Cardiomyopathy Disease Background and Overview
6. Dilated Cardiomyopathy Patient Journey
7. Dilated Cardiomyopathy Epidemiology and Patient Population
8. Dilated Cardiomyopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Dilated Cardiomyopathy Unmet Needs
10. Key Endpoints of Dilated Cardiomyopathy Treatment
11. Dilated Cardiomyopathy Marketed Products
12. Dilated Cardiomyopathy Emerging Therapies
13. Dilated Cardiomyopathy Seven Major Market Analysis
14. Attribute Analysis
15. Dilated Cardiomyopathy Market Outlook (7 major markets)
16. Dilated Cardiomyopathy Access and Reimbursement Overview
17. KOL Views on the Dilated Cardiomyopathy Market.
18. Dilated Cardiomyopathy Market Drivers
19. Dilated Cardiomyopathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report –
https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm-market-insights
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
Functional Electrical Stimulation (FES) Devices Market
As per DelveInsight, the Global “Functional Electrical Stimulation Devices Market” will grow at a CAGR of 8.2% during the forecast period from 2021 to 2026. Some of the key companies in the Functional Electrical Stimulation (FES) Devices market include HASOMED GmbH, Restorative Therapies, Bioness Inc., Trulife, Otto Bock, Odstock Medical Limited, Hobbs Rehabilitation, MotoMed, Medline Industries, LP, and others.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/